References
1 Guan, W. J. et al. Clinical
Characteristics of Coronavirus Disease 2019 in China. N Engl J
Med 382 , 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
2 Wu, C. et al. Risk Factors
Associated With Acute Respiratory Distress Syndrome and Death in
Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.JAMA Intern Med , doi:10.1001/jamainternmed.2020.09942763184
[pii] (2020).
3 Sanders, J. M., Monogue, M. L.,
Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic Treatments for
Coronavirus Disease 2019 (COVID-19): A Review. JAMA ,
doi:10.1001/jama.2020.6019
2764727 [pii] (2020).
4 Horby, P. et al. Effect of
Dexamethasone in Hospitalized Patients with COVID-19: Preliminary
Report. medRxiv , 2020.2006.2022.20137273,
doi:10.1101/2020.06.22.20137273 (2020).
5 Rhen, T. & Cidlowski, J. A.
Antiinflammatory action of glucocorticoids–new mechanisms for old
drugs. N Engl J Med 353 , 1711-1723, doi:353/16/1711
[pii]10.1056/NEJMra050541 (2005).
6 Pyrillou, K., Chairakaki, A. D.,
Tamvakopoulos, C. & Andreakos, E. Dexamethasone induces omega3-derived
immunoresolvents driving resolution of allergic airway inflammation.J Allergy Clin Immunol 142 , 691-695 e694,
doi:S0091-6749(18)30612-2 [pii]10.1016/j.jaci.2018.04.004 (2018).
7 Serhan, C. N. Pro-resolving lipid
mediators are leads for resolution physiology. Nature510 , 92-101, doi:10.1038/nature13479nature13479 [pii]
(2014).
8 Cherpokova, D. et al.Resolvin D4 attenuates the severity of pathological thrombosis in mice.Blood 134 , 1458-1468,
doi:10.1182/blood.2018886317blood.2018886317 [pii] (2019).
9 Norris, P. C., Libreros, S. &
Serhan, C. N. Resolution metabolomes activated by hypoxic environment.Sci Adv 5 , eaax4895, doi:10.1126/sciadv.aax4895aax4895
[pii] (2019).
10 van Zaane, B. et al.Systematic review on the effect of glucocorticoid use on procoagulant,
anti-coagulant and fibrinolytic factors. J Thromb Haemost8 , 2483-2493, doi:10.1111/j.1538-7836.2010.04034.xJTH4034
[pii] (2010).
11 Koltsida, O. et al.Toll-like receptor 7 stimulates production of specialized pro-resolving
lipid mediators and promotes resolution of airway inflammation.EMBO Mol Med 5 , 762-775, doi:10.1002/emmm.201201891
(2013).
12 Morita, M. et al. The lipid
mediator protectin D1 inhibits influenza virus replication and improves
severe influenza. Cell 153 , 112-125,
doi:10.1016/j.cell.2013.02.027S0092-8674(13)00216-X [pii] (2013).
13 Tam, V. C. et al. Lipidomic
profiling of influenza infection identifies mediators that induce and
resolve inflammation. Cell 154 , 213-227,
doi:10.1016/j.cell.2013.05.052S0092-8674(13)00695-8 [pii] (2013).
14 Avdeev, S. et al. Low
prevalence of bronchial asthma and chronic obstructive lung disease
among intensive care unit patients with COVID-19. Allergy ,
doi:10.1111/all.14420 (2020).
15 Schwarz, B. et al. Severe
SARS-CoV-2 infection in humans is defined by a shift in the serum
lipidome resulting in dysregulation of eicosanoid immune mediators.medRxiv , doi:10.1101/2020.07.09.20149849 (2020).